← All trials
NCT05001737
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 15, 2021
- Primary completion
- Aug 31, 2023
- Completion date
- Aug 31, 2023
- First posted
- Aug 12, 2021
- Last posted
- Nov 10, 2021
- Enrollment
- 41
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Swedish Orphan BiovitrumLead sponsor
- Swedish Orphan BiovitrumStudy chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.